Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Materials

DSM Boosts Role In Biomedical Materials

by Michael McCoy
May 7, 2012 | A version of this story appeared in Volume 90, Issue 19

DSM plans to acquire Kensey Nash, a U.S.-based biomedical materials company, for about $360 million. The deal, approved by Kensey Nash’s board, represents a 33% premium over Kensey Nash’s recent share price. Based in Exton, Pa., Kensey Nash makes medical device parts using collagen and synthetic polymer technology. It expects to have sales of $90 million for the fiscal year ending June 30. DSM CEO Feike Sijbesma says his firm is well positioned to expand in biomedical materials because of its presence in both the life sciences and materials sectors.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.